U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187960) titled 'Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma' on Sept. 17.
Brief Summary: Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Follicular Lymphoma
Intervention:
DRUG: TQB2825 Injection
TQB2825 is a Cluster of Differentiation 3 (CD3) x Cluster of Differentiation 20 (CD20) bispecific antibody.
DRUG: Rituximab Injection
Rituximab combined with Chemotherapy (Rituximab, ...